ATTANA AB Stock Börse Stuttgart

Equities

SE0010547273

Biotechnology & Medical Research

End-of-day quote Börse Stuttgart 5-day change 1st Jan Change
- EUR -.--% Intraday chart for ATTANA AB -.--% -.--%

Financials

Sales 2022 13.11M 1.24M 1.15M 1.69M Sales 2023 6.82M 644K 600K 880K Capitalization 26.99M 2.55M 2.38M 3.48M
Net income 2022 -14M -1.32M -1.23M -1.81M Net income 2023 -13M -1.23M -1.14M -1.68M EV / Sales 2022 3.42 x
Net Debt 2022 3.24M 306K 285K 419K Net Debt 2023 3.18M 300K 280K 411K EV / Sales 2023 4.43 x
P/E ratio 2022
-2.84 x
P/E ratio 2023
-1.96 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 43.5%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 23-09-17
Founder 54 01-12-31
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member 71 16-12-31
Chairman 61 15-09-30
Founder 54 01-12-31
More insiders
Attana AB is a Sweden-based biotechnology company specializing in in vitro characterization of molecular interactions mimicking in vivo conditions. The Company develops proprietary label-free biosensors, based on the Quartz Crystal Microbalance (QCM) technology, for biochemical, crude, sera and cell-based assays. Its products and research services are used by pharmaceutical and biotechnology companies to quality control the production line of a biological pharmaceutical or gain insight into advanced dynamic features of target molecules, as well as by academic institutions within the life sciences. Attana’s biosensors are used to determine specificity, kinetics and affinity, among other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.
Calendar
More about the company

Annual profits - Rate of surprise